Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors.
CDP-choline was given to patients with Alzheimer's disease (AD) at a daily dose of 1000 mg/day p.o. for one month. This compound slightly improved mental performance, tended to reduce theta activity in fronto-temporal regions, increasing alpha power in occipital areas, and enhanced cerebrovascular perfusion by increasing blood flow velocity and reducing pulsatility and resistance indexes. In addition, CDP-choline diminished histamine and interleukin-1 levels in blood and serum, respectively, and increased plasma TNF.
Cacabelos
R
R
Institute for CNS Disorders, Basic and Clinical Neurosciences Research Center, La Coruña, Spain.
Caamaño
J
J
Gómez
M J
MJ
Fernández-Novoa
L
L
Franco-Maside
A
A
Alvarez
X A
XA
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000523:psychology; D001931:Brain Mapping; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003071:Cognition / Q000187:drug effects*; D003566:Cytidine Diphosphate Choline / Q000627:therapeutic use*; D016207:Cytokines / Q000097:blood; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006632:Histamine / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged
D016207:Cytokines; D003566:Cytidine Diphosphate Choline; D006632:Histamine